切换至 "中华医学电子期刊资源库"

中华医学超声杂志(电子版) ›› 2021, Vol. 18 ›› Issue (06) : 564 -569. doi: 10.3877/cma.j.issn.1672-6448.2021.06.005

所属专题: 乳腺超声

浅表器官超声影像学

超声结合钼靶成像及Ki-67表达对乳腺癌新辅助化疗疗效的预测价值
唐益勇1, 李晓琴,2, 施燕芸2, 范光磊3   
  1. 1. 116044 大连医科大学第二临床学院
    2. 213164 南京医科大学附属常州第二人民医院超声科
    3. 213164 南京医科大学附属常州第二人民医院核医学科
  • 收稿日期:2020-04-28 出版日期:2021-06-01
  • 通信作者: 李晓琴

Value of ultrasonography combined with mammographic features and Ki-67 index in predicting efficacy of neoadjuvant chemotherapy for breast cancer

Yiyong Tang1, Xiaoqin Li,2, Yanyun Shi2, Guanglei Fan3   

  1. 1. Second Clinical College of Dalian Medical University, Dalian 116044, China
    2. Department of Ultrasound, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou 213164, China
    3. Department of Nuclear Medicine, the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou 213164, China
  • Received:2020-04-28 Published:2021-06-01
  • Corresponding author: Xiaoqin Li
引用本文:

唐益勇, 李晓琴, 施燕芸, 范光磊. 超声结合钼靶成像及Ki-67表达对乳腺癌新辅助化疗疗效的预测价值[J/OL]. 中华医学超声杂志(电子版), 2021, 18(06): 564-569.

Yiyong Tang, Xiaoqin Li, Yanyun Shi, Guanglei Fan. Value of ultrasonography combined with mammographic features and Ki-67 index in predicting efficacy of neoadjuvant chemotherapy for breast cancer[J/OL]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2021, 18(06): 564-569.

目的

探讨常规超声、钼靶X线影像学特征及Ki-67阳性表达率对乳腺癌新辅助化疗后达到病理完全缓解(pCR)的预测价值。

方法

回顾性选取2014年11月至2019年11月在常州市第二人民医院行新辅助化疗治疗的68例乳腺癌患者,患者行化疗前均接受乳腺超声和钼靶X线检查,且均经粗针穿刺取得病理和免疫组化结果。依据新辅助化疗疗效评价标准,将患者分为pCR组和非pCR组。应用单因素及多因素Logistic回归方法分析乳腺癌新辅助化疗后获得pCR的独立预测因素。

结果

68例患者中,12例达到pCR,56例为非pCR,pCR率为17.6%。将单因素分析有统计学意义的肿瘤后方回声类型、钼靶影像中边缘特征、Ki-67阳性表达率及雌激素受体(ER)表达结果纳入二元Logistic回归进行多因素分析。结果表明,超声成像中病灶后方回声无衰减(OR=0.045,95%CI:0.005~0.453)、钼靶成像中病灶边缘无毛刺(OR=0.129,95%CI:0.023~0.720)、Ki-67高表达(OR=0.045,95%CI:0.004~0.546)是pCR的独立预测因素。

结论

超声显示肿瘤后方回声无衰减、钼靶X线影像中肿块边缘光滑无毛刺以及Ki-67高表达可预测乳腺癌患者新辅助化疗术后的病理缓解程度,术前影像学检查及免疫组化Ki-67测定对临床乳腺癌治疗方案的选择具有一定指导意义。

Objective

To assess the value of ultrasound combined with mammographic features and Ki-67 index in predicting the efficacy of neoadjuvant chemotherapy for breast cancer.

Methods

Sixty-eight patients with breast cancer who received neoadjuvant chemotherapy at Changzhou Second People's Hospital from November 2014 to November 2019 were examined by ultrasonography and mammography before chemotherapy. Pathological and immunohistochemically results were obtained by biopsy. According to the efficacy of neoadjuvant chemotherapy, the patients were divided into either a pathologic complete response (pCR) group or a non-pCR group. Univariate and multivariate Logistic regression analyses were performed to analyze the independent predictors of pCR after neoadjuvant chemotherapy for breast cancer.

Results

Of the 68 patients ,12 achieved pCR and 56 did not, with a pCR rate of 17.6%. The statistically significant parameters identified in the univariate analysis, such as the type of posterior echo of tumor, the edge characteristics of tumor in mammography, and the positive expression rate of Ki-67 or estrogen receptor (ER), were included in binary logistic regression for multivariate analysis. The results showed that absence of posterior shadowing on ultrasound (odds ratio [OR]=0.045, 95% CI: 0.005-0.453), absence of mammographic spiculation (OR=0.128, 95% CI: 0.023-0.720), and high Ki-67 expression (OR=0.045, 95% CI: 0.004-0.546)were independent predictors of pCR.

Conclusion

The absence of posterior shadowing on ultrasound, absence of mammographic speculation, and high Ki-67 high could predict the degree of pathological remission in breast cancer patients after neoadjuvant chemotherapy. Preoperative imaging examination and immunohistochemical Ki-67 detection have appreciated guiding significance for the selection of clinical treatment for breast cancer.

表1 新辅助化疗后获得pCR的单因素分析 [例(%)]
图1 新辅助化疗后未获得病理完全缓解的乳腺癌患者(女性,37岁)术前超声、钼靶X线、穿刺病理及术后病理图像。图a 为常规超声声像图示右乳低回声肿块,后方回声衰减;图b 为钼靶X线示等密度肿块影,内见点状钙化,边缘模糊,呈毛刺征;图c 为穿刺病理诊断为浸润性导管癌ER(+)(HE ×100);图d 为术后病理诊断浸润性导管癌,伴坏死,侵犯神经组织,脉管内见癌栓(HE ×100)
图2 新辅助化疗后获得病理完全缓解的乳腺癌患者(女性,52岁)术前超声、钼靶X线、穿刺病理及术后病理图像。图a为常规超声声像图示左乳低回声肿块,后方回声无衰减;图b 为钼靶X线示高密度肿块影,内见点状钙化,边缘无毛刺;图c 为穿刺病理诊断为浸润性导管癌ER(-)(HE ×100);图d 为术后病理诊断未见癌组织残留(HE ×100)
表2 预测新辅助化疗pCR的各因素赋值表
表3 新辅助化疗后获得pCR的Logistic多因素回归分析
1
施海建, 丁洁, 姥义. 高频超声联合弹性应变率比值与磁共振成像诊断乳腺癌的临床价值比较 [J/OL]. 中华医学超声杂志(电子版), 2020,17(10): 993-998.
2
沈雷, 张宏伟. 乳腺癌新辅助化疗的研究进展 [J]. 复旦学报(医学版), 2016, 43(2): 244-248.
3
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update [J]. J Clin Oncol, 2006, 24(12): 1940-1949.
4
Asaoka M, Narui K, Suganuma N, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy [J]. Eur J Surg Oncol, 2019, 45(12): 2289-2294.
5
Tan MC, Al MF, Gao F, et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer [J]. Am J Surg, 2009, 198(4): 520-525.
6
Vaidya JS, Massarut S, Vaidya HJ, et al. Rethinking neoadjuvant chemotherapy for breast cancer [J]. BMJ, 2018, 360: j5913.
7
Nishimura R, Osako T, Nishiyama Y, et al. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer [J]. Mol Clin Oncol, 2014, 2(6): 1062-1068.
8
Zhu X, Chen L, Huang B, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer [J]. Sci Rep, 2020, 10(1): 225.
9
朱庆莉, 姜玉新. 乳腺影像报告与数据系统指南(第5版)超声内容更新介绍 [J/CD]. 中华医学超声杂志(电子版), 2016, 13(1): 5-7.
10
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 [J]. Ann Oncol, 2017, 28(8): 1700-1712.
11
Goldhirsch A, Wood WC, Coates , et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011 [J]. Ann Oncol, 2011, 22(8): 1736-1747.
12
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
13
周洁莹, 史宪全, 王知力, 等. 剪切波弹性成像技术定量评价乳腺癌新辅助化疗疗效的价值 [J/CD]. 中华医学超声杂志(电子版), 2015, 12(9): 723-727.
14
Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18 [J]. J Natl Cancer Inst Monogr, 2001, (30): 96-102.
15
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol, 2008, 26(5): 778-785.
16
Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer [J]. Br J Cancer, 2004, 91(12): 2012-2017.
17
Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy [J]. Ann Oncol, 2008, 19(3): 465-472.
18
Au FW, Ghai S, Lu FI, et al. Histological grade and immunohistochemical biomarkers of breast cancer: correlation to ultrasound features [J]. J Ultrasound Med, 2017, 36(9): 1883-1894.
19
Aho M, Irshad A, Ackerman SJ, et al. Correlation of sonographic features of invasive ductal mammary carcinoma with age, tumor grade, and hormone-receptor status [J]. J Clin Ultrasound, 2013, 41(1): 10-17.
20
Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer [J]. Br J Cancer, 2005, 92(1): 147-155.
21
桑蝶, 王佳玉, 袁芃, 等. Ki-67与乳腺癌临床病理特征及新辅助化疗疗效的相关性 [J]. 癌症进展, 2015, 13(3): 291-297.
22
Liu S, Wu XD, Xu WJ, et al. Is there a correlation between the presence of a spiculated mass on mammogram and Luminal A subtype breast cancer? [J]. Korean J Radiol, 2016,17(6): 846-852.
23
Lamb PM, Perry NM, Vinnicombe SJ, et al. Correlation between ultrasound characteristics, mammographic findings and histological grade in patients with invasive ductal carcinoma of the breast [J]. Clin Radiol, 2000, 55(1): 40-44.
24
Sturesdotter L, Sandsveden M, Johnson K, et al. Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype [J]. Sci Rep, 2020, 10(1): 20814.
25
Mukhtar RA, Yau C, Rosen M, et al. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) [J]. Ann Surg Oncol, 2013, 20(12): 3823-3830.
26
Park S, Yoon JH, Sohn J, et al. Magnetic resonance imaging after completion of neoadjuvant chemotherapy can accurately discriminate between no residual carcinoma and residual ductal carcinoma in situ in patients with triple-negative breast cancer [J]. PLoS One, 2016, 11(2): e149347.
27
Sueta A, Yamamoto Y, Hayashi M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? [J]. Surgery, 2014, 155(5): 927-935.
28
Chen C, Zhang Y, Huang Z, et al. Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer [J]. Cancer Biol Med, 2019, 16(3): 575-586.
29
Yoshioka T, Hosoda M, Yamamoto M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer [J]. Breast Cancer, 2015, 22(2): 185-191.
30
王勒, 郑红梅, 吴新红, 等. 乳腺癌临床病理特征和分子分型对新辅助化疗疗效及预后的预测价值 [J]. 中华实用诊断与治疗杂志, 2019, 33(8): 739-743.
[1] 章建全, 程杰, 陈红琼, 闫磊. 采用ACR-TIRADS评估甲状腺消融区的调查研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 966-971.
[2] 罗辉, 方晔. 品管圈在提高甲状腺结节细针穿刺检出率中的应用[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 972-977.
[3] 杨忠, 时敬业, 邓学东, 姜纬, 殷林亮, 潘琦, 梁泓, 马建芳, 王珍奇, 张俊, 董姗姗. 产前超声在胎儿22q11.2 微缺失综合征中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 852-858.
[4] 孙佳丽, 金琳, 沈崔琴, 陈晴晴, 林艳萍, 李朝军, 徐栋. 机器人辅助超声引导下经皮穿刺的体外实验研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 884-889.
[5] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[6] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[7] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[8] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[11] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[12] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[13] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
阅读次数
全文
6
HTML PDF
最新录用 在线预览 正式出版 最新录用 在线预览 正式出版
0 0 0 0 0 6

  来源 本网站 其他网站
  次数 2 4
  比例 33% 67%

摘要
409
最新录用 在线预览 正式出版
0 0 408
  来源 本网站 其他网站
  次数 247 162
  比例 60% 40%